```html

Yttrium‑Induced Pneumonitis

Overview

Yttrium‑induced pneumonitis is an inflammatory lung condition that occurs after exposure to yttrium‑containing compounds, most commonly the radiopharmaceutical yttrium‑90 (Y‑90) microspheres used in selective internal radiation therapy (SIRT) for liver cancer. The yttrium particles may embolize to the pulmonary vasculature, triggering an immune‑mediated inflammatory reaction that impairs gas exchange.

• Who it affects: Adults undergoing Y‑90 SIRT, particularly those with pre‑existing lung disease, high cumulative lung radiation dose, or impaired hepatic‑pulmonary shunting.
• Prevalence: Severe pneumonitis is rare, reported in < 1 % of patients receiving Y‑90 therapy; however, mild sub‑clinical changes are detected in up to 5 % on routine imaging (Mayo Clinic, 2022).
• Geography: Cases have been documented worldwide, wherever Y‑90 SIRT is performed (North America, Europe, Asia).

Symptoms

The clinical picture ranges from asymptomatic radiographic changes to acute respiratory failure. Common symptoms include:

Respiratory

• Dyspnea: Shortness of breath that may be exertional initially, progressing to at‑rest in severe cases.
• Cough: Usually dry, but can become productive if secondary infection develops.
• Chest tightness or pressure: Often described as a mild “weight” on the chest.
• Wheezing or crackles: Heard on auscultation in moderate‑to‑severe disease.

Systemic

• Fever: Low‑grade (<38 °C) in inflammatory phase; higher fevers may suggest infection.
• Fatigue and malaise: Due to impaired oxygenation.
• Weight loss: Usually occurs only with chronic inflammation.

Severe/Advanced

• Hypoxia: Oxygen saturation < 90 % on room air.
• Rapid breathing (tachypnea): > 22 breaths/min.
• Chest pain: Rare, may indicate pleural involvement.
• Hemoptysis: Uncommon, but a red‑flag sign.

Causes and Risk Factors

Primary cause

Yttrium‑induced pneumonitis results from radiation‑induced lung injury when Y‑90 microspheres or soluble yttrium compounds lodge in pulmonary capillaries. The beta radiation (maximum energy 2.28 MeV) causes endothelial damage, oxidative stress, and release of pro‑inflammatory cytokines (TNF‑α, IL‑6). The inflammatory cascade leads to alveolar‑interstitial infiltrates and, over time, fibrosis.

Key risk factors

• High lung radiation dose: Cumulative dose ≥ 30 Gy (based on dosimetric calculations) markedly raises risk.
• Significant hepatopulmonary shunt: Measured by technetium‑99m macroaggregated albumin (MAA) scan; shunt fraction > 20 % is a strong predictor.
• Pre‑existing lung disease: COPD, interstitial lung disease, or asthma.
• Age ≥ 65 years: Age‑related decline in pulmonary reserve.
• Concurrent chemotherapy or immunotherapy: May potentiate inflammation.
• Renal or hepatic dysfunction: Alters yttrium clearance, increasing systemic exposure.

Diagnosis

Because symptoms overlap with infection, heart failure, and other drug‑induced lung injuries, a systematic approach is essential.

Clinical evaluation

• Detailed history of Y‑90 therapy (date, dose, shunt fraction, concurrent meds).
• Physical exam focusing on respiratory findings.

Imaging studies

• Chest X‑ray: May show bilateral infiltrates; useful for rapid screening.
• High‑resolution CT (HRCT): Gold standard; demonstrates ground‑glass opacities, centrilobular nodules, and later fibrotic changes.
• Ventilation‑perfusion (V/Q) scan: Helps differentiate embolic phenomena.

Laboratory tests

• Complete blood count (CBC) – look for leukocytosis vs. eosinophilia.
• Arterial blood gas (ABG) – assesses hypoxemia and acid‑base status.
• Serum inflammatory markers (CRP, ESR) – non‑specific but may track response.

Functional assessment

• Pulmonary function tests (PFTs): Reduced diffusing capacity (DLCO) is an early indicator.
• 6‑minute walk test: Objective measure of functional limitation.

Exclusion of other causes

Microbiologic cultures (sputum, BAL), echocardiography (to rule out heart failure), and, if needed, lung biopsy may be performed when the diagnosis remains uncertain.

Treatment Options

Management focuses on reducing inflammation, supporting oxygenation, and preventing progression to fibrosis.

Pharmacologic therapy

• Corticosteroids: Prednisone 0.5–1 mg/kg/day for 4–6 weeks, followed by a gradual taper. Early initiation (< 2 weeks from symptom onset) improves outcomes (NIH, 2021).
• Immunomodulators: In steroid‑refractory cases, agents such as azathioprine or mycophenolate mofetil have been used off‑label.
• Antibiotics: Empiric coverage only if bacterial infection cannot be excluded.
• Bronchodilators: Short‑acting β‑agonists for wheezing; inhaled corticosteroids may provide adjunct relief.

Supportive care

• Oxygen therapy: Titrate to maintain SpO₂ ≥ 92 % (≥ 88 % in COPD).
• Non‑invasive ventilation (NIV): Consider for moderate respiratory distress.
• Pulmonary rehabilitation: Improves exercise tolerance and quality of life.

Procedural interventions

• Therapeutic bronchoscopy: Reserved for airway obstruction or to obtain BAL samples.
• Lung transplant: Considered only for end‑stage, irreversible fibrosis in selected patients.

Lifestyle and adjunct measures

• Smoking cessation – essential to prevent further lung injury.
• Vaccinations (influenza, pneumococcal, COVID‑19) – reduce superimposed infections.

Living with Yttrium‑Induced Pneumonitis

Even after acute inflammation resolves, many patients experience lingering dyspnea and reduced exercise capacity. The following strategies help maintain function and quality of life.

Daily management tips

• Monitor symptoms: Keep a diary of breathlessness, cough, and temperature.
• Medication adherence: Take steroids exactly as prescribed; never stop abruptly without tapering.
• Breathing techniques: Pursed‑lip breathing and diaphragmatic breathing reduce dyspnea.
• Stay active: Low‑impact aerobic activities (walking, stationary cycling) 30 min most days, guided by a pulmonary rehab therapist.
• Hydration: Adequate fluid intake keeps secretions thin.
• Environmental control: Avoid smoke, strong fragrances, and dust exposure.

Follow‑up schedule

Typical follow‑up after an acute episode includes:

• Clinic visit with pulmonary function testing at 4 weeks, 3 months, and 6 months.
• Repeat HRCT at 3–6 months if symptoms persist or worsen.
• Long‑term monitoring every 6–12 months for fibrosis progression.

Prevention

Because Y‑90 therapy is often essential for cancer control, the goal is to mitigate lung exposure while preserving oncologic benefit.

Pre‑procedure strategies

• Accurate dosimetry: Use technetium‑99m MAA scintigraphy to quantify hepatopulmonary shunt; patients with shunt > 20 % may need dose reduction or alternative therapy.
• Limit cumulative lung dose: Follow the NCCN recommendations—total lung dose should not exceed 30 Gy.
• Optimize baseline lung function: Treat COPD or asthma before Y‑90, and encourage smoking cessation at least 4 weeks prior.

Post‑procedure precautions

• Immediate post‑embolization chest X‑ray to detect early embolic migration.
• Early steroid prophylaxis (e.g., dexamethasone 4 mg IV intra‑procedure) has shown modest reduction in inflammatory markers in small series (Cleveland Clinic, 2020).
• Educate patients on early symptom recognition and prompt reporting.

Complications

If untreated or inadequately managed, yttrium‑induced pneumonitis can lead to:

• Progressive pulmonary fibrosis: Permanent loss of lung compliance.
• Chronic hypoxemic respiratory failure: May require long‑term oxygen therapy.
• Secondary infections: Steroid therapy predisposes to bacterial, fungal, or viral pneumonias.
• Pulmonary hypertension: Resulting from chronic vascular injury.
• Reduced survival: Studies link severe pneumonitis to a 15‑20 % decrease in overall survival after Y‑90 SIRT (Journal of Hepatology, 2022).

When to Seek Emergency Care

---

**Sources:** Mayo Clinic. Yttrium‑90 radioembolization safety profile. 2022; National Institutes of Health. Radiation‑induced lung injury. 2021; Centers for Disease Control and Prevention. Radiation emergency guidelines. 2020; Cleveland Clinic. Prophylactic steroids in Y‑90 therapy. 2020; Journal of Hepatology. Outcomes after Y‑90 SIRT. 2022; World Health Organization. Radiation safety & public health. 2021.

```